(Q45856532)

17 December 2017

title

Home treatment with recombinant activated factor VII in patients with factor VIII inhibitors: the advantages of early intervention (English)

1 reference

17 December 2017

main subject

patient

0 references

author

Pier Mannuccio Mannucci

series ordinal

3

object named as

Mannucci PM

1 reference

17 December 2017

author name string

Santagostino E

series ordinal

1

1 reference

17 December 2017

Gringeri A

series ordinal

2

1 reference

17 December 2017

language of work or name

English

0 references

publication date

1 January 1999

1 reference

17 December 2017

British Journal of Haematology

published in

1 reference

17 December 2017

volume

104

1 reference

17 December 2017

issue

1

1 reference

17 December 2017

page(s)

22-26

1 reference

17 December 2017

Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII.

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.1999.01128.X

Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.1999.01128.X

A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.1999.01128.X

Myocardial infarction complicating activated prothrombin complex concentrate substitution in patient with hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.1999.01128.X

10.1046/J.1365-2141.1999.01128.X

21 January 2018

Identifiers

DOI

1 reference

17 December 2017

1 reference

17 December 2017